Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single- and Multiple-Dose Study of Inhaled MK-5475 in Healthy Japanese and Caucasian Male Participants
jRCT2031210073Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of frespaciguat in pulmonary hypertension (PH) (4 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability after single-dose inhaled MK-5475 and Safety and tolerability after multiple-dose inhaled MK-5475. Started May 2021; status: completed.
02
Drugs
frespaciguat
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on jRCT2031210073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210073.